-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Advances -X- _ O
in -X- _ O
molecular -X- _ O
diagnostics -X- _ O
have -X- _ O
implicated -X- _ O
newly-discovered -X- _ O
respiratory -X- _ O
viruses -X- _ O
in -X- _ O
the -X- _ O
pathogenesis -X- _ O
of -X- _ O
pneumonia. -X- _ O
We -X- _ O
aimed -X- _ O
to -X- _ O
determine -X- _ O
the -X- _ O
prevalence -X- _ O
and -X- _ O
clinical -X- _ O
characteristics -X- _ O
of -X- _ O
human -X- _ B-Patient
bocavirus -X- _ I-Patient
( -X- _ I-Patient
hBoV -X- _ I-Patient
) -X- _ I-Patient
, -X- _ I-Patient
human -X- _ I-Patient
rhinovirus -X- _ I-Patient
( -X- _ I-Patient
hRV -X- _ I-Patient
) -X- _ I-Patient
, -X- _ I-Patient
polyomavirus-WU -X- _ I-Patient
( -X- _ I-Patient
WUPyV -X- _ I-Patient
) -X- _ I-Patient
and -X- _ I-Patient
–KI -X- _ I-Patient
( -X- _ I-Patient
KIPyV -X- _ I-Patient
) -X- _ I-Patient
and -X- _ I-Patient
human -X- _ I-Patient
coronaviruses -X- _ I-Patient
( -X- _ I-Patient
CoV -X- _ I-Patient
) -X- _ I-Patient
-OC43 -X- _ I-Patient
, -X- _ I-Patient
-NL63 -X- _ I-Patient
, -X- _ I-Patient
-HKU1 -X- _ I-Patient
and -X- _ I-Patient
-229E -X- _ I-Patient
among -X- _ I-Patient
children -X- _ I-Patient
hospitalized -X- _ I-Patient
with -X- _ I-Patient
lower -X- _ I-Patient
respiratory -X- _ I-Patient
tract -X- _ I-Patient
infections -X- _ I-Patient
( -X- _ I-Patient
LRTI -X- _ I-Patient
) -X- _ I-Patient
. -X- _ O
METHODS -X- _ O
: -X- _ O
Multiplex -X- _ O
real-time -X- _ O
reverse- -X- _ O
transcriptase -X- _ O
polymerase -X- _ O
chain -X- _ O
reaction -X- _ O
was -X- _ O
undertaken -X- _ O
on -X- _ O
archived -X- _ O
nasopharyngeal -X- _ O
aspirates -X- _ O
from -X- _ O
HIV-infected -X- _ B-Patient
and -X- _ I-Patient
–uninfected -X- _ I-Patient
children -X- _ I-Patient
( -X- _ I-Patient
< -X- _ I-Patient
2 -X- _ I-Patient
years -X- _ I-Patient
age -X- _ I-Patient
) -X- _ I-Patient
hospitalized -X- _ I-Patient
for -X- _ I-Patient
LRTI -X- _ I-Patient
, -X- _ O
who -X- _ O
had -X- _ O
been -X- _ O
previously -X- _ O
investigated -X- _ O
for -X- _ O
respiratory -X- _ O
syncytial -X- _ O
virus -X- _ O
, -X- _ O
human -X- _ O
metapneumovirus -X- _ O
, -X- _ O
parainfluenza -X- _ O
I–III -X- _ O
, -X- _ O
adenovirus -X- _ O
and -X- _ O
influenza -X- _ O
A -X- _ O
/ -X- _ O
B. -X- _ O
RESULTS -X- _ O
: -X- _ O
At -X- _ B-Outcome
least -X- _ I-Outcome
one -X- _ I-Outcome
of -X- _ I-Outcome
these -X- _ I-Outcome
viruses -X- _ I-Outcome
were -X- _ I-Outcome
identified -X- _ I-Outcome
in -X- _ I-Outcome
274 -X- _ I-Outcome
( -X- _ I-Outcome
53.0 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
of -X- _ I-Outcome
517 -X- _ I-Outcome
and -X- _ I-Outcome
in -X- _ I-Outcome
509 -X- _ I-Outcome
( -X- _ I-Outcome
54.0 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
of -X- _ I-Outcome
943 -X- _ I-Outcome
LRTI-episodes -X- _ I-Outcome
in -X- _ I-Outcome
HIV-infected -X- _ I-Outcome
and -X- _ I-Outcome
-uninfected -X- _ I-Outcome
children -X- _ I-Outcome
, -X- _ I-Outcome
respectively. -X- _ I-Outcome
Human -X- _ I-Outcome
rhinovirus -X- _ I-Outcome
was -X- _ I-Outcome
the -X- _ I-Outcome
most -X- _ I-Outcome
prevalent -X- _ I-Outcome
in -X- _ I-Outcome
HIV-infected -X- _ I-Outcome
( -X- _ I-Outcome
31.7 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
–uninfected -X- _ I-Outcome
children -X- _ I-Outcome
( -X- _ I-Outcome
32.0 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
followed -X- _ I-Outcome
by -X- _ I-Outcome
CoV-OC43 -X- _ I-Outcome
( -X- _ I-Outcome
12.2 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
hBoV -X- _ I-Outcome
( -X- _ I-Outcome
9.5 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
in -X- _ I-Outcome
HIV-infected -X- _ I-Outcome
; -X- _ I-Outcome
and -X- _ I-Outcome
by -X- _ I-Outcome
hBoV -X- _ I-Outcome
( -X- _ I-Outcome
13.3 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
WUPyV -X- _ I-Outcome
( -X- _ I-Outcome
11.9 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
in -X- _ I-Outcome
HIV-uninfected -X- _ I-Outcome
children. -X- _ I-Outcome
Polyomavirus-KI -X- _ I-Outcome
( -X- _ I-Outcome
8.9 -X- _ I-Outcome
% -X- _ I-Outcome
vs. -X- _ I-Outcome
4.8 -X- _ I-Outcome
% -X- _ I-Outcome
; -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.002 -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
CoV-OC43 -X- _ I-Outcome
( -X- _ I-Outcome
12.2 -X- _ I-Outcome
% -X- _ I-Outcome
vs. -X- _ I-Outcome
3.6 -X- _ I-Outcome
% -X- _ I-Outcome
; -X- _ I-Outcome
p -X- _ I-Outcome
< -X- _ I-Outcome
0.001 -X- _ I-Outcome
) -X- _ I-Outcome
were -X- _ I-Outcome
more -X- _ I-Outcome
prevalent -X- _ I-Outcome
in -X- _ I-Outcome
HIV-infected -X- _ I-Outcome
than -X- _ I-Outcome
– -X- _ I-Outcome
uninfected -X- _ I-Outcome
children. -X- _ I-Outcome
Combined -X- _ I-Outcome
with -X- _ I-Outcome
previously-tested -X- _ I-Outcome
viruses -X- _ I-Outcome
, -X- _ I-Outcome
respiratory -X- _ I-Outcome
viruses -X- _ I-Outcome
were -X- _ I-Outcome
identified -X- _ I-Outcome
in -X- _ I-Outcome
60.9 -X- _ I-Outcome
% -X- _ I-Outcome
of -X- _ I-Outcome
HIV-infected -X- _ I-Outcome
and -X- _ I-Outcome
78.3 -X- _ I-Outcome
% -X- _ I-Outcome
of -X- _ I-Outcome
HIV-uninfected -X- _ I-Outcome
children. -X- _ I-Outcome
The -X- _ I-Outcome
newly -X- _ I-Outcome
tested -X- _ I-Outcome
viruses -X- _ I-Outcome
were -X- _ I-Outcome
detected -X- _ I-Outcome
at -X- _ I-Outcome
high -X- _ I-Outcome
frequency -X- _ I-Outcome
in -X- _ I-Outcome
association -X- _ I-Outcome
with -X- _ I-Outcome
other -X- _ I-Outcome
respiratory -X- _ I-Outcome
viruses -X- _ I-Outcome
, -X- _ I-Outcome
including -X- _ I-Outcome
previously- -X- _ I-Outcome
investigated -X- _ I-Outcome
viruses -X- _ I-Outcome
( -X- _ I-Outcome
22.8 -X- _ I-Outcome
% -X- _ I-Outcome
in -X- _ I-Outcome
HIV-infected -X- _ I-Outcome
and -X- _ I-Outcome
28.5 -X- _ I-Outcome
% -X- _ I-Outcome
in -X- _ I-Outcome
HIV–uninfected -X- _ I-Outcome
children -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
CONCLUSIONS -X- _ O
: -X- _ O
We -X- _ O
established -X- _ O
that -X- _ O
combined -X- _ O
with -X- _ O
previously-investigated -X- _ O
viruses -X- _ O
, -X- _ O
at -X- _ O
least -X- _ O
one -X- _ O
respiratory -X- _ O
virus -X- _ O
was -X- _ O
identified -X- _ O
in -X- _ O
the -X- _ O
majority -X- _ O
of -X- _ O
HIV-infected -X- _ O
and -X- _ O
HIV-uninfected -X- _ O
children -X- _ O
hospitalized -X- _ O
for -X- _ O
LRTI. -X- _ O
The -X- _ O
high -X- _ O
frequency -X- _ O
of -X- _ O
viral -X- _ O
co-infections -X- _ O
illustrates -X- _ O
the -X- _ O
complexities -X- _ O
in -X- _ O
attributing -X- _ O
causality -X- _ O
to -X- _ O
specific -X- _ O
viruses -X- _ O
in -X- _ O
the -X- _ O
aetiology -X- _ O
of -X- _ O
LRTI -X- _ O
and -X- _ O
may -X- _ O
indicate -X- _ O
a -X- _ O
synergetic -X- _ O
role -X- _ O
of -X- _ O
viral -X- _ O
co-infections -X- _ O
in -X- _ O
the -X- _ O
pathogenesis -X- _ O
of -X- _ O
childhood -X- _ O
LRTI -X- _ O
. -X- _ O

